Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients

• DOI: 10.1111/j.1478-3231.2011.02727.x
• Publication Date: 2011-12-30T17:06:19Z
• Authors: Akihito Tsubota; Noritomo Shimada; Kai Yoshizawa; Tomomi Furihata; Rie Agata; Yoko Yumoto; Hiroshi Abe; Makiko Ika; Yoshihisa Namiki; Kan Chiba; Kiyotaka Fujise; Norio Tada; Yoshio Aizawa
• Keywords: ITPA; Pegylated interferon; SNP; Interleukin 28B; Hepatitis C

Standard-dose ribavirin is crucial for the standard-of-care treatment of chronic hepatitis C virus (HCV) infection. Equilibrative nucleoside transporter 1 (ENT1), encoded by SLC29A1 gene, main that imports into human hepatocytes.To determine whether single nucleotide polymorphisms (SNPs) at gene could influence probability response compared with other baseline and host genetic factors.A total 526 East Asian patients monoinfected HCV genotype 1b who had received pegylated interferon alpha plus therapy were enrolled in this study. They assigned randomly to derivation confirmatory groups. SNPs related IL28B, ITPA genes genotyped using real-time detection polymerase chain reaction. Factors associated sustained virological (SVR) analysed multiple logistic regression analysis.Multivariate analysis group identified six variables significantly independently SVR: age [P = 0.023, odds ratio (OR) 0.97], gender (P 0.0047, OR 2.25), platelet count 0.00017, 1.11), viral load 0.00026, 0.54), IL28B SNP rs12979860 1.09 × 10(-7) , 8.68) rs6932345 0.030, 1.85). Using model constructed these independent variables, positive negative predictive values accuracy 73.3, 70.1 71.9% respectively. For group, they 71.4, 84.6 75.3% The also rapid response.The major ENT1 was one factors influencing response, although impact on prediction small.